S. Ogbagabriel

发表

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer

Daniel J. Freeman, Sameer Doshi, R. Radinsky, 2012, Molecular Cancer.

O-0011FREQUENCY OF S492R MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR: ANALYSIS OF PLASMA DNA FROM METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH PANITUMUMAB OR CETUXIMAB MONOTHERAPY

Tae Won Kim, P. Ruff, M. Boedigheimer, 2014 .

Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors

Daniel J. Freeman, M. Rothe, R. Radinsky, 2008 .

Securin is overexpressed in breast cancer

F. Waldman, S. Bose, M. Fernando, 2005, Modern Pathology.

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor

Daniel J. Freeman, Todd Juan, T. Bush, 2009, Molecular Cancer Therapeutics.

309 POSTER Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models

Daniel J. Freeman, M. Rothe, R. Radinsky, 2008 .

Fully human Anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo

Daniel J. Freeman, S. Hartmann, M. Rothe, 2008 .

Abstract B171: U3‐1287 (AMG 888), a fully human anti‐HER3 mAb, demonstrates in vitro and in vivo efficacy in NSCLC models

Daniel J. Freeman, R. Radinsky, Matthias Schneider, 2009 .

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor

Daniel J. Freeman, T. Bush, R. Radinsky, 2009, Molecular Cancer Therapeutics.

Abstract A182: U3–1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu model of human squamous cell carcinoma of the head and neck (SCCHN).

Daniel J. Freeman, R. Radinsky, T. Hettmann, 2011 .

Mechanisms mediating the negative interaction between oxaliplatin (Ox) and epidermal growth factor receptor (EGFR) inhibitors in patients (pts) with KRAS mutant (MT) colorectal cancer (CRC).

Daniel J. Freeman, R. Radinsky, Gloria Juan, 2012 .

Abstract B167: Identifying first in human (FIH) doses and schedule of U3‐1287 (AMG 888), a fully human anti‐HER3 mAb, based on preclinical pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data

Daniel J. Freeman, R. Radinsky, Bing‐Bing Yang, 2009 .